Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsOPHTHALMICGeneric

VASOCON-A

ANTAZOLINE PHOSPHATE; NAPHAZOLINE HYDROCHLORIDE

Standard Dose
0.5%;0.05%
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview VASOCON-A is listed in Drugs@FDA under application 018746 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient ANTAZOLINE PHOSPHATE; NAPHAZOLINE HYDROCHLORIDE Form and strength SOLUTION/DROPS;OPHTHALMIC - 0.5%;0.05% Sponsor NOVARTIS Submission history Latest submission status date: 2001-01-02 00:00:00.

Structured Monograph

Clinical summary

Approval overview VASOCON-A is listed in Drugs@FDA under application 018746 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient ANTAZOLINE PHOSPHATE; NAPHAZOLINE HYDROCHLORIDE Form and strength SOLUTION/DROPS;OPHTHALMIC - 0.5%;0.05% Sponsor NOVARTIS Submission history Latest submission status date: 2001-01-02 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
VASOCON-A (ANTAZOLINE PHOSPHATE; NAPHAZOLINE HYDROCHLORIDE) | Drug Monograph | MedicHelpline